Susie Jun

6.8k citations

25 papers · 4.9k indexed · 5 hit papers · h-index 15

Impact in

Orthopedics and Sports Medicine top 0.5%
- Bone and Joint Diseases
Oncology top 0.5%
- Bone health and treatments
- Cancer Diagnosis and Treatment

Papers in ⓘ

Hematology 10
- Chronic Myeloid Leukemia Treatments 4
- Platelet Disorders and Treatments 3
Genetics 8
- Chronic Lymphocytic Leukemia Research 5
- Myeloproliferative Neoplasms: Diagnosis and Treatment 4

Co-authors: Allan Lipton (9 shared papers)Roger Dansey (7 shared papers)Michelle Fan (5 shared papers)Qi Jiang (4 shared papers)Guenther G. Steger (5 shared papers)Katia Tonkin (5 shared papers)Ada Braun (4 shared papers)María Eugenia Ibarrarán Viniegra (4 shared papers)
Journals: Journal of Clinical Oncology (9 papers)Blood (7 papers)Clinical Cancer Research (2 papers)British Journal of Haematology (1 paper)American Journal of Hematology (1 paper)
Partner nations: United States Australia Canada

In The Last Decade

Susie Jun

25 papers receiving 4.8k citations

Hit Papers

5 papers align trajectories log scale

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials 2012 · 420 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2012 European Journal of Cancer
2012 Clinical Cancer Research
2011 Journal of Clinical Oncology
2010 Journal of Clinical Oncology
2010 The Lancet Oncology

Peers

Countries citing papers authored by Susie Jun

Since Specialization

Citations

This map shows the geographic impact of Susie Jun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susie Jun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susie Jun more than expected).

Fields of papers citing papers by Susie Jun

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susie Jun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susie Jun. The network helps show where Susie Jun may publish in the future.

Co-authors

The 25 scholars most cited alongside Susie Jun, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Susie Jun Line = papers co-authored together Susie Jun links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study Journal of Clinical Oncology ·Alison Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G. Steger, Katia Tonkin, Richard H. De Boer, Mikhail Lichinitser, Yasuhiro Fujiwara, Denise A. Yardley, María Eugenia Ibarrarán Viniegra, Michelle Fan, Qi Jiang, Roger Dansey, Susie Jun, Ada Braun Hit paper breakdown →	2010	1102
2	Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma Journal of Clinical Oncology ·David H. Henry, Luís Costa, François Goldwasser, Vera Hirsh, Vânia Hungria, Jana Prausová, Giorgio V. Scagliotti, H.P. Sleeboom, Andrew Spencer, Saroj Vadhan‐Raj, Roger von Moos, Wolfgang Willenbacher, Penella J. Woll, Jianming Wang, Qi Jiang, Susie Jun, Roger Dansey, Howard Yeh Hit paper breakdown →	2011	877
3	Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study The Lancet Oncology ·David M. Thomas, Robert M. Henshaw, Keith M. Skubitz, Sant P. Chawla, Arthur P. Staddon, Jean‐Yves Blay, Martine P. Roudier, J. W. G. Smith, Zhishen Ye, Winnie Sohn, Roger Dansey, Susie Jun Hit paper breakdown →	2010	516
4	Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials European Journal of Cancer ·Allan Lipton, Karim Fizazi, Alison Stopeck, David H. Henry, Janet E. Brown, Denise A. Yardley, Gary Richardson, Salvatore Siena, Pablo Maroto, Michael Clemens, Boris Bilynskyy, Veena Charu, Philippe Beuzeboc, Michael Rader, María Eugenia Ibarrarán Viniegra, Fred Saad, Chunlei Ke, Ada Braun, Susie Jun Hit paper breakdown →	2012	420
5	Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates Journal of Clinical Oncology ·Karim Fizazi, Allan Lipton, Xavier Mariette, Jean‐Jacques Body, Yasmin Rahim, Julie R. Gralow, Guozhi Gao, Ling Wu, Winnie Sohn, Susie Jun	2009	388
6	Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast Cancer Journal of Clinical Oncology ·Georgiana K. Ellis, Henry G. Bone, Rowan T. Chlebowski, Devchand Paul, Silvana Spadafora, J. W. G. Smith, Michelle Fan, Susie Jun	2008	342
7	Denosumab Induces Tumor Reduction and Bone Formation in Patients with Giant-Cell Tumor of Bone Clinical Cancer Research ·Daniel Branstetter, Scott D. Nelson, J. Carlos Manivel, Jean‐Yves Blay, Sant P. Chawla, David M. Thomas, Susie Jun, Ira Jacobs Hit paper breakdown →	2012	332
8	Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases Journal of Clinical Oncology ·Allan Lipton, Guenther G. Steger, Jazmín Meneses Figueroa, Cristina Alvarado, Philippe Solal‐Céligny, Jean-Jacques Body, Richard de Boer, Rossana Berardi, Pere Gascón, Katia Tonkin, Robert E. Coleman, Alexander Paterson, Mark Peterson, Michelle Fan, A. Kinsey, Susie Jun	2007	293
9	Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy British Journal of Haematology ·David J. Kuter, James B. Bussel, Adrian C. Newland, Ross Baker, Roger M. Lyons, Jeffrey S. Wasser, Jean‐François Viallard, Gail Macik, Mathias Rummel, Kun Nie, Susie Jun	2013	203
10	Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors Supportive Care in Cancer ·David H. Henry, Saroj Vadhan‐Raj, Vera Hirsh, Roger von Moos, Vânia Hungria, Luís Costa, Penella J. Woll, Giorgio V. Scagliotti, Geoffrey Smith, Amy Feng, Susie Jun, Roger Dansey, Howard Yeh	2013	130
11	Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy Clinical Cancer Research ·Allan Lipton, Guenther G. Steger, Jazmín Meneses Figueroa, Cristina Alvarado, Philippe Solal‐Céligny, J.J. Body, Richard de Boer, Rossana Berardi, Pere Gascón, Katia Tonkin, Robert E. Coleman, Alexander Paterson, Guozhi Gao, A. Kinsey, Mark Peterson, Susie Jun	2008	118
12	An open‐label, phase 2 trial of denosumab in the treatment of relapsed or plateau‐phase multiple myeloma American Journal of Hematology ·Ravi Vij, Noemi Horvath, Andrew Spencer, Kerry Taylor, Saroj Vadhan‐Raj, Robert Vescio, J. W. G. Smith, Yi Qian, Howard Yeh, Susie Jun	2009	72
13	RANKL inhibition in the treatment of bone metastases Current Opinion in Supportive and Palliative Care ·Allan Lipton, Susie Jun	2008	34
14	Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study Blood ·David J. Kuter, James B. Bussel, Adrian C. Newland, Jeffrey S. Wasser, Roger M. Lyons, James N. George, Gail Macik, Kun Nie, Susie Jun	2010	25
15	Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (Int-1) Risk Myelodysplastic Syndrome (MDS): Results of a Randomized, Double-Blind, Placebo(PBO)-Controlled Study Blood ·Aristoteles Giagounidis, Ghulam J. Mufti, Hagop M. Kantarjian, Pierre Fenaux, Mikkael A. Sekeres, Jeff Szer, Andrea Kuendgen, Uwe Platzbecker, Gianluca Gaïdano, W Wiktor-Jędrzejczak, Kuolung Hu, Allen S. Yang, Susie Jun	2011	16
16	Sustained Hemostatic Platelet Counts in Adults with Immune Thrombocytopenia (ITP) Following Cessation of Treatment with the TPO Receptor Agonist Romiplostim: Report of 9 Cases, Blood ·James B. Bussel, Francesco Rodeghiero, Roger M. Lyons, Barry Firstenberg, Joanne Joseph, Craig M. Kessler, Louis Terriou, Roberto Stasi, Paul Chang, Susie Jun	2011	13
17	An Open-Label, Phase 2 Trial of Denosumab in the Treatment of Relapsed (R) or Plateau-Phase (PP) Multiple Myeloma (MM). Blood ·Ravi Vij, Noemi Horvath, Andrew Spencer, Kerry Taylor, Saroj Vadhan‐Raj, J. W. G. Smith, Yi Qian, Susie Jun	2007	12
18	Interim Analysis Of Dose-Escalation Stage Of a Phase 1b Study Evaluating Safety and Pharmacology Of GS-9820, a Second-Generation, Selective, PI3Kd-Inhibitor in Recurrent Lymphoid Malignancies Blood ·Arnon P. Kater, Sanne H. Tonino, Marie José Kersten, Anton Hagenbeek, Marjolein Spiering, M. H. van Oers, Xin Yan, S. Ramanathan, Maria Aiello, Susie Jun	2013	11
19	Dose-Response Analyses Of Momelotinib (CYT387), a JAK1 and JAK2 Inhibitor, From a Phase I/II Study (CCL09101) In Treatment Of Myelofibrosis Blood ·Xin Yan, Lixin Shao, Wei Deng, Demi Niforos, Mark Kowalski, Linda M. Bavisotto, Jun Kawashima, Susie Jun, Helen Collins, S. Ramanathan	2013	5
20	Reply to V. Fusco et al Journal of Clinical Oncology ·Alison Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G. Steger, Katia Tonkin, Richard H. De Boer, Mikhail Lichinitser, Yasuhiro Fujiwara, Denise A. Yardley, María Eugenia Ibarrarán Viniegra, Michelle Fan, Qi Jiang, Roger Dansey, Susie Jun, Ada Braun	2011	4

About Susie Jun

Susie Jun is a scholar working on Hematology, Genetics, Oncology, Radiology, Nuclear Medicine and Imaging and Orthopedics and Sports Medicine, having authored 25 papers that have together received 4.9k indexed citations. Recurring topics across this work include Bone health and treatments (15 papers), Radiopharmaceutical Chemistry and Applications (8 papers), Cancer Diagnosis and Treatment (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Bone Metabolism and Diseases (5 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Platelet Disorders and Treatments (3 papers). The work is most often cited by research in Orthopedics and Sports Medicine (1.2k citations), Oncology (3.7k citations), Oral Surgery (584 citations), Rheumatology (1.1k citations) and Hematology (586 citations). Susie Jun has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include Allan Lipton, Roger Dansey, Michelle Fan, Qi Jiang, Guenther G. Steger, Katia Tonkin, Ada Braun, María Eugenia Ibarrarán Viniegra, Alison Stopeck and Denise A. Yardley. Their work appears in journals such as Journal of Clinical Oncology, Blood, Clinical Cancer Research, British Journal of Haematology and American Journal of Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact